Water soluble 5 FC complexes, preliminary pharmacological studies

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 65, Issue 3, 2009, Pages 431-435

  Spulber, Mariana ^a   Miron, Liviu ^b   Mares, Mihai ^b   Nastasa, Valentin ^b   Pinteala, Mariana ^a   Fifere, Adrian ^a   Harabagiu, Valeria ^a   Simionescu, Bogdan C ^a  

^a Petru Poni Institute of Macromolecular Chemistry   (Oman)

^b UNIVERSITY OF AGRICULTURAL SCIENCES AND VETERINARY MEDICINE   (Romania)

Author keywords

Antifungal activity; Flucytosine; MIC 50 and MIC 90

Indexed keywords

EID: 76749165666     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-009-9594-x     Document Type: Article

References (13)

1. Spulber, M., Pinteala, M., Fifere, A., Harabagiu, V., Simionescu, B. C.: Inclusion complexes of 5-flucytosine with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: characterization in aqueous solution and in solid state. J. Incl. Phenom. Macrocycl. Chem. 62, 117-125 (2008). doi: 10. 1007/s10847-008-9446-0.
2. Vermes, A., Guchelaar, A. J., Dankert, J.: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46, 171-179 (2000). doi: 10. 1093/jac/46. 2. 171.
3. Hedges, A. R.: Industrial applications of cyclodextrins. Chem. Rev. 98, 2035-2044 (1998). doi: 10. 1021/cr970014w.
4. Loftsson, T., Brewster, M. E.: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025 (1996). doi: 10. 1021/js950534b.
5. Spulber, M., Pinteala, M., Harabagiu, V., Simionescu, B. C.: Inclusion complexes of sulconazole with β-cyclodextrin and hydroxypropyl β-cyclodextrin: characterization in aqueous solution and in solid state. J. Incl. Phenom. Macrocycl. Chem. 61, 41-51 (2008). doi: 10. 1007/s10847-007-9391-3.
6. Spulber, M., Pinteala, M., Fifere, A., et al.: Water soluble complexes of methyl β-cyclodextrin and sulconazole nitrate. J. Incl. Phenom. Macrocycl. Chem. 62, 135-142 (2008). doi: 10. 1007/s10847-008-9448-y.
7. Francis, P., Walsh, T. J.: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15, 1003-1018 (1992).
8. Scholer, H. J.: Flucytosine. In: Speller, E. D. (eds.) Antifungal Chemotherapy, pp. 35-106. Wiley, Chichester (1997).
9. Viviani, M. A.: Flucytosine-what is its future? J. Antimicrob. Chemother. 35, 241-244 (1995). doi: 10. 1093/jac/35. 2. 241.
10. National Committee Standards for Clinical Laboratory: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard, 2nd edn. National Committee for Clinical Laboratory Standards, Wayne, Pa (2002). M27-A2.
11. Dixon, W. J., Mood, A. M.: A method for obtaining and analyzing sensitivity data. J. Am. Stat. Assoc. 43, 109-126 (1948). doi: 10. 2307/2280071.
12. OECD (2000) Guidance Document on Acute Oral Toxicity. Environmental Health and Safety Monograph Series on Testing and Assessment No. 24.
13. OECD (2000) Guidance document on the Recognition, Assessment and use Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation. Environmental Health and Safety Monograph Series on Testing and Assessment No 19.